BSI worsening at 12 weeks was prognostic for progression-free survival ( HR = 2.14 per BSI doubling , P < 0.001 ) and OS ( HR = 1.58 , P = 0.033 ) in multivariate analyses including baseline BSI and TASQ treatment .